Sector analysts revisited the IOVA stock forecast after competitor setbacks, which may give Iovance a market timing edge. Price projections now range $9.20–$12.70 depending on FDA review windows. Also Read: 10 Largest Biotech Hedge Funds and Their Top Stock Picks To see Spark’s full report on IOVA stock, click here . In recent trading, IOVA stock forecast models adjusted upward after positive sentiment from peer cell therapy approvals. Price is hovering near $10.40, with options market activity indicating expectations of higher volatility ahead of Q4 updates.
